155 related articles for article (PubMed ID: 12523458)
21. Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children.
Hazra R; Balis FM; Tullio AN; DeCarlo E; Worrell CJ; Steinberg SM; Flaherty JF; Yale K; Poblenz M; Kearney BP; Zhong L; Coakley DF; Blanche S; Bresson JL; Zuckerman JA; Zeichner SL
Antimicrob Agents Chemother; 2004 Jan; 48(1):124-9. PubMed ID: 14693529
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily.
Elion R; Cohen C; Ward D; Ruane P; Ortiz R; Reddy YS; Ebrahimi R; McColl D; Kearney B; Fisher A; Flaherty J;
HIV Clin Trials; 2008; 9(4):213-24. PubMed ID: 18753116
[TBL] [Abstract][Full Text] [Related]
23. Tenofovir disoproxil fumarate.
Grim SA; Romanelli F
Ann Pharmacother; 2003 Jun; 37(6):849-59. PubMed ID: 12773076
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial.
Kahn J; Lagakos S; Wulfsohn M; Cherng D; Miller M; Cherrington J; Hardy D; Beall G; Cooper R; Murphy R; Basgoz N; Ng E; Deeks S; Winslow D; Toole JJ; Coakley D
JAMA; 1999 Dec 22-29; 282(24):2305-12. PubMed ID: 10612317
[TBL] [Abstract][Full Text] [Related]
25. Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults.
Barditch-Crovo P; Deeks SG; Collier A; Safrin S; Coakley DF; Miller M; Kearney BP; Coleman RL; Lamy PD; Kahn JO; McGowan I; Lietman PS
Antimicrob Agents Chemother; 2001 Oct; 45(10):2733-9. PubMed ID: 11557462
[TBL] [Abstract][Full Text] [Related]
26. Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection.
Lyseng-Williamson KA; Reynolds NA; Plosker GL
Drugs; 2005; 65(3):413-32. PubMed ID: 15669881
[TBL] [Abstract][Full Text] [Related]
27. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
Molina JM; Cahn P; Grinsztejn B; Lazzarin A; Mills A; Saag M; Supparatpinyo K; Walmsley S; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
Lancet; 2011 Jul; 378(9787):238-46. PubMed ID: 21763936
[TBL] [Abstract][Full Text] [Related]
28. Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.
Aurpibul L; Cressey TR; Sricharoenchai S; Wittawatmongkol O; Sirisanthana V; Phongsamart W; Sudjaritruk T; Chokephaibulkit K
Pediatr Infect Dis J; 2015 Apr; 34(4):392-7. PubMed ID: 25760566
[TBL] [Abstract][Full Text] [Related]
29. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults.
Deeks SG; Barditch-Crovo P; Lietman PS; Hwang F; Cundy KC; Rooney JF; Hellmann NS; Safrin S; Kahn JO
Antimicrob Agents Chemother; 1998 Sep; 42(9):2380-4. PubMed ID: 9736567
[TBL] [Abstract][Full Text] [Related]
30. Tubulopathy consecutive to tenofovir-containing antiretroviral therapy in two patients infected with human immunodeficiency virus-1.
Breton G; Alexandre M; Duval X; Prie D; Peytavin G; Leport C; Vildei JL
Scand J Infect Dis; 2004; 36(6-7):527-8. PubMed ID: 15307594
[TBL] [Abstract][Full Text] [Related]
31. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study.
Schooley RT; Ruane P; Myers RA; Beall G; Lampiris H; Berger D; Chen SS; Miller MD; Isaacson E; Cheng AK;
AIDS; 2002 Jun; 16(9):1257-63. PubMed ID: 12045491
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.
Dore GJ; Cooper DA; Pozniak AL; DeJesus E; Zhong L; Miller MD; Lu B; Cheng AK; ;
J Infect Dis; 2004 Apr; 189(7):1185-92. PubMed ID: 15031786
[TBL] [Abstract][Full Text] [Related]
33. Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.
von Wyl V; Yerly S; Böni J; Bürgisser P; Klimkait T; Battegay M; Bernasconi E; Cavassini M; Furrer H; Hirschel B; Vernazza PL; Rickenbach M; Ledergerber B; Günthard HF;
Clin Infect Dis; 2008 Apr; 46(8):1299-309. PubMed ID: 18444871
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK
HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898
[TBL] [Abstract][Full Text] [Related]
35. K65R, TAMs and tenofovir.
Miller MD
AIDS Rev; 2004; 6(1):22-33. PubMed ID: 15168738
[TBL] [Abstract][Full Text] [Related]
36. Tenacious tenofovir struts its stuff in a virtual ICAAC.
Huff B
GMHC Treat Issues; 2001 Oct; 15(10):9-11. PubMed ID: 11727571
[No Abstract] [Full Text] [Related]
37. High rate of virological failure in maintenance antiretroviral therapy with didanosine and tenofovir.
León A; Mallolas J; Martinez E; De Lazzari E; Pumarola T; Larrousse M; Milincovic A; Lonca M; Blanco JL; Laguno M; Biglia A; Gatell JM
AIDS; 2005 Oct; 19(15):1695-7. PubMed ID: 16184042
[TBL] [Abstract][Full Text] [Related]
38. A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patients.
Girard PM; Cabié A; Michelet C; Verdon R; Katlama C; Mercié P; Morand-Joubert L; Pétour P; Monchecourt F; Chêne G; Trylesinski A;
J Antimicrob Chemother; 2009 Jul; 64(1):126-34. PubMed ID: 19403652
[TBL] [Abstract][Full Text] [Related]
39. [Tenofovir in Study 903. Also effective and tolerable in first-line therapy].
MMW Fortschr Med; 2002 Aug; 144(33-34):61. PubMed ID: 12380158
[No Abstract] [Full Text] [Related]
40. The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients.
Winston A; Mandalia S; Pillay D; Gazzard B; Pozniak A
AIDS; 2002 Oct; 16(15):2087-9. PubMed ID: 12370512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
